Laura E Dichtel, Kathleen E Corey, Melanie S Haines, Mark L Chicote, Hang Lee, Allison Kimball, Caitlin Colling, Tracey G Simon, Michelle T Long, Jad Husseini, Miriam A Bredella, Karen K Miller
CONTEXT: Overweight and obesity are associated with relative growth hormone (GH) deficiency, which has been implicated in the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is a progressive disease without effective treatments. OBJECTIVE: We hypothesized that GH administration would reduce hepatic steatosis in individuals with overweight/obesity and NAFLD. METHODS: In this 6-month randomized, double-blind, placebo-controlled trial of low-dose GH administration, 53 adults aged 18 to 65 years with BMI ≥25 kg/m2 and NAFLD without diabetes were randomized to daily subcutaneous GH or placebo, targeting insulin-like growth factor 1 (IGF-1) to the upper normal quartile...
November 17, 2023: Journal of Clinical Endocrinology and Metabolism